MDNAF - Medicenna's Potential Best-In-Class IL-2 Superkine Program Making Progress
Medicenna Therapeutics Corp. [TSX:MDNA] (OTCQB:MDNAF) is a Toronto based clinical-stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines.
Superkines can be engineered as short or long-acting therapeutics or fused with cell-killing proteins in order to generate Empowered Cytokines ("ECs") that can deliver potent toxins to the cancer cells without harming adjacent healthy cells.
Medicenna believes that its engineered Superkines can also be fused with other types of proteins such as antibodies to generate novel "immunocytokines" or combined with other treatment modalities such as checkpoint inhibitors, Chimeric Antigen Receptor